GET DAILY SIGNALSSOPHiA GENETICS (SOPH) Stock Declines -22.8% in Recent Month Despite Accelerating Revenue
Key Takeaways
- SOPH shares declined roughly 22.8% over the trailing 30 days, falling from about $8.07 to near $6.23, even as revenue growth accelerated.
- The pullback erased much of a sharp summer rally, though the stock remains modestly higher over the trailing three-month period.
- Third-quarter 2026 revenue rose 25% year over year to $24.3 million on record platform volume, yet shares still sold off around results day.
- Ongoing net losses and a mid-2026 equity offering have kept investor sentiment cautious despite a reaccelerating top line.
- Liquid biopsy, U.S. market expansion, and the BioPharma business remain the company's most visible growth levers.
- For deeper valuation context and expectations, review SOPH's Price Targets, Earnings, and Forecast pages.
SOPHiA GENETICS and Its Focus on Precision Medicine
SOPH is a Switzerland-based, AI-native healthcare technology company focused on data-driven precision medicine. Its flagship product, SOPHiA DDM™, is a cloud-native, consumption-based software-as-a-service platform that analyzes genomic and multimodal data to generate clinical insights for cancer and rare-disease care. The platform serves a global network of hospitals, laboratories, and biopharma institutions across more than 70 countries, supporting both clinical diagnostics and biopharmaceutical research and development.
Investors follow SOPH for its exposure to the intersection of artificial intelligence and healthcare, its recurring consumption-based revenue model, and its network effect, in which data flowing through the platform continually improves the underlying algorithms. The company's competitive strengths include a decentralized testing model that enables institutions to run sophisticated analyses in-house, a broad regulatory footprint, and a growing roster of strategic partnerships in liquid biopsy and companion diagnostics. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Price Moves: 30 Days Versus the Quarter
Over the trailing 30 days, SOPH shares moved from approximately $8.07 to about $6.23, a decline of roughly 22.8%. The move was not linear: the stock fell sharply through the first half of October, touching a low near $6.49 on October 19, recovered into the upper $7 range in late October, and then dropped again in early November as third-quarter results were reported.
The trailing-quarter picture is more mixed. From roughly $5.69 in early August, the stock surged to an intraday-era peak near $8.92 in late August following strong second-quarter results, before giving back much of that advance. Net of the volatility, the stock is up about 9% over the trailing three months, underscoring how much of the recent decline reflects a retracement of an earlier rally rather than a new low.
Factors Behind the Latest 30-Day Decline
The most recent 30-day period was defined by a sharp sell-off that began in early October, with the shares dropping roughly 9.5% in a single session in the first week of the month and continuing lower into mid-October. No single company-specific event clearly explains the initial leg down, which is consistent with profit-taking after a strong summer run and broader investor caution around an unprofitable, higher-multiple growth name.
Positive developments during the period failed to halt the slide. On October 8, SOPHiA GENETICS and Myriad Genetics (MYGN) announced a collaboration to advance prostate-cancer genomic instability score technology, an agreement aimed at precision-oncology applications. The shares nonetheless remained under pressure.
In early November, SOPHiA GENETICS reported third-quarter results showing revenue of $24.3 million, up 25% year over year, and a record 118,000 platform analyses, up 19%. The company guided full-year revenue toward the upper end of its $94 million to $96 million range, though it cited a partial foreign-exchange offset. Despite the strong top line, the stock fell by more than 12% in the most recent session, reflecting the market's focus on a slightly wider net loss and the absence of a full guidance raise.
Drivers of Performance Over the Past Quarter
The broader three-month trend was shaped by strong second-quarter results. In August, the company reported second-quarter revenue of about $23.3 million, up 27% year over year, with roughly 60% volume growth in the U.S., and raised its full-year revenue guidance to $94 million to $96 million from $92 million to $94 million. That print, combined with a completed CEO transition to Ross Muken effective July 1, powered the August rally toward the stock's recent peak.
Strategic announcements also supported the narrative over the quarter, including a companion-diagnostics collaboration with AstraZeneca (AZN), a memorandum of understanding with Memorial Sloan Kettering Cancer Center toward a precision-oncology joint venture, and the Myriad Genetics prostate-score collaboration. Offsetting these positives, a June underwritten public offering of roughly 10.5 million ordinary shares created a dilution overhang, while persistent net losses kept a lid on sentiment.
Key Areas to Watch Going Forward
Looking ahead, investors will focus on the company's seasonally strongest fourth quarter and any updates to full-year guidance. The most important financial milestone is the stated goal of reaching positive adjusted EBITDA in the second half of 2027, a target that would mark a meaningful inflection for a company still reporting net losses.
Operationally, the ramp of the MSK-ACCESS liquid biopsy application, U.S. market momentum, and the rollout of companion-diagnostics programs remain key catalysts. Companion-diagnostic milestone payments tied to agreements such as the AstraZeneca collaboration are expected to contribute primarily in 2027. Foreign-exchange movements, reimbursement trends, and competitive dynamics in precision oncology also bear watching, as does any further capital-raising activity following the mid-2026 offering.
My Experience With Tickeron’s AI Tools
In my research process I frequently review Tickeron’s AI Trading Bots to understand how automated strategies are positioning around names like SOPH. The platform offers a range of bots with different timeframes and risk parameters, which gives me an additional data point when evaluating volatility and potential entry or exit levels. This approach has helped me stay objective when sentiment turns negative after otherwise solid results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SOPH's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for SOPH turned positive on October 26, 2026. Looking at past instances where SOPH's MACD turned positive, the stock continued to rise in 49 of 54 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SOPH's RSI Oscillator exited the oversold zone, 14 of 17 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on SOPH as a result. In 104 of 119 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
Following a +5.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where SOPH advanced for three days, in 205 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
SOPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
SOPH moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SOPH crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SOPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for SOPH entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.282) is normal, around the industry mean (4.699). P/E Ratio (-6.129) is within average values for comparable stocks, (13.248). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.452) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. SOPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SOPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement